Uri Ben-David, PhD, Tel Aviv University
Elsa Logarinho, PhD, University of Porto
Stefano Santaguida, PhD, University of Milan and European Institute of Oncology
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
Castello Dal Pozzo
Via Visconti 8
28040 Oleggio Castello, Italy
We propose a meeting, entitled “Aneuploidy in cancer development, prognosis and treatment”, that will bring together researchers from the cancer aneuploidy community. In particular, we envision a platform of creative thinking and scientific cooperation, gathering scientists with expertise and interests in studying how chromosome imbalances arise during tumorigenesis and how they can be targeted for cancer therapy.
During the meeting, participants will have the opportunity to discuss one of the most complex questions in cancer biology, namely whether and how aneuploidy contributes to tumorigenesis, and how this hallmark of cancer can be targeted therapeutically. This question is extremely timely and is currently addressed by several labs that are exploiting the powerful advances in genetics, cell biology and cancer biology to deconstruct the genetic makeup of cancer cells.
Focused discussions, prompted by talks from both junior and senior researchers, will invigorate research on these important problems. The well-established format of the Forbeck meetings will guarantee interactions among scientists using complementary approaches that will fuel collaborative and innovative thinking. Finally, this will also encourage the sharing of valuable resources and reagents across labs. We strongly believe that this meeting will empower researchers with new ideas and scientific allies long after the meeting has adjourned.
Notably, this meeting will follow the 2016 Annual Forbeck Forum on Chromosomal Instability and Aneuploidy. However, on top of the exciting developments that the field has seen in the past few years, the focus of the proposed meeting will be different from that of the 2016 meeting, and will emphasize the role of aneuploidy in tumor development, prognosis and treatment.
|Samuel Bakhoum, MD, PhD||Memorial Sloan Kettering Cancer Center|
|Ivana Barbaric, PhD||The University of Sheffield|
|Uri Ben-David, PhD||Tel Aviv University|
|Don Cleveland, PhD||Ludwig Institute for Cancer Research/UCSD|
|Floris Foijer, PhD||ERIBA - University Medical Center Groningen|
|Eva Gonzalez Suarez, PhD||CNIO (Centro Nacional de Investigaciones Oncológicas)|
|Shai Izraeli, MD||Schneider Children's Medical Center and Tel Aviv University|
|Elsa Logarinho, PhD||Instituto de Biologia Molecular e Celular - Universidade do Porto|
|Sarah McClelland, PhD, BSc||Barts Centre - Cancer Research UK|
|Rene Medema, PhD, PhD||Netherlands Cancer Institute|
|Cristina Montagna, PhD||Albert Einstein College of Medicine|
|Stefano Santaguida, PhD||University of Milan and European Institute of Oncology|
|Rocio Sotillo Roman, PhD||German Cancer Research Center (DKFZ)|
|Charles Swanton, MBPhD, FRCP, FMedSci||Francis Crick Institute & UCL Cancer Institute|
|Stephen Taylor, PhD||University of Manchester|
|Eduardo Torres, PhD||UMASS Medical School|
|Elsa Bernard, PhD||Memorial Sloan Kettering Cancer Center|
|Pippa Cosper, MD, PhD||University of Wisconsin, Madison|
|Elena Kuzmin, PhD||McGill University|
|Thomas Watkins, PhD||University College London and the Francis Crick Institute|
The Malpensa Airport (MXP) is the preferred airport as it is only 25 minutes from the meeting location.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.Submit Abstract
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!